Zhejiang Jingxin Pharmaceutical News

Zhejiang Jingxin Pharmaceutical (002020.SZ): has repurchased 4.00% of its shares.

On March 21, 2023, Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that as of March 21, 2025, the company repurchased 34.462528 million shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 4.00% of the company's current total share capital. The highest Fill Price for the repurchased shares was 13.93 yuan/share, and the lowest Fill Price was 11.86 yuan/share, with a total transaction amount of 0.434 billion yuan (excluding transaction fees).

Gelonghui FinanceMar 21 17:18

Express News | Zhejiang Jingxin Pharmaceutical: Adjusted the buyback fund limit to 0.7 billion yuan.

BreakingsMar 7 17:35

Zhejiang Jingxin Pharmaceutical (002020.SZ): The revenue from the business in the USA accounts for a small proportion of the company's overall business revenue.

Gelonghui, March 5th丨Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the revenue from its Business in the USA accounts for a small proportion of the company's overall Business revenue, and the additional tariffs imposed by the USA are expected to have no significant impact on the company's performance.

Gelonghui FinanceMar 5 16:39

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Zhejiang Jingxin Pharmaceutical (002020.SZ): A total of 3.01% of the company's shares have been repurchased.

Gelonghui, on March 2nd, reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that as of February 28, 2025, the company repurchased 25.936483 million shares through a dedicated securities account for share buybacks using a centralized bidding method, accounting for 3.01% of the company's total share capital. The highest Fill Price for the repurchased shares was 12.98 yuan/share, while the lowest Fill Price was 11.86 yuan/share, with a total transaction amount of 319.7463 million yuan (excluding transaction fees).

Gelonghui FinanceMar 2 15:49

Zhejiang Jingxin Pharmaceutical (002020.SZ): The company has not yet made any plans for gene therapy.

On February 18, Glonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company currently does not have any plans for gene therapy.

Gelonghui FinanceFeb 18 17:21

Zhejiang Jingxin Pharmaceutical (002020.SZ): has repurchased a total of 2.07% of the shares.

On February 13, Gelonghui announced that Zhejiang Jingxin Pharmaceutical (002020.SZ) disclosed that as of February 13, 2025, the company repurchased 17.787429 million shares through its dedicated stock repurchase account via a centralized bidding method, accounting for 2.07% of the company's current total share capital. The highest Fill Price for the purchased shares was 12.92 yuan/share, the lowest Fill Price was 11.86 yuan/share, and the total amount spent was 0.219 billion yuan (excluding transaction costs).

Gelonghui FinanceFeb 13 17:03

Zhejiang Jingxin Pharmaceutical (002020.SZ): First buyback of 0.86 million company shares.

Gelonghui, January 12th丨Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that on January 10, 2025, the company repurchased 860,000 shares through a special securities account for stock buybacks via centralized bidding, accounting for 0.10% of the company's total share capital. The highest Fill Price for the repurchased shares was 12.16 yuan/share, while the lowest Fill Price was 11.99 yuan/share, with a total transaction value of 10.3827 million yuan (excluding transaction fees).

Gelonghui FinanceJan 12 15:45

Huafu Securities: The demand potential in the lipid-lowering drug Industry is enormous, and several Innovative Drugs are about to receive data catalysis.

Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.

Zhitong FinanceJan 9 14:33

Express News | Zhejiang Jingxin Pharmaceutical plans to use 0.2 billion yuan to 0.4 billion yuan of its own funds to repurchase shares.

BreakingsJan 8 16:31

Express News | The Pacific Securities: The change in policies for generic drug formulations presents a good opportunity for the development of the Industry.

BreakingsJan 8 08:50

Express News | The National Healthcare Security Administration held a symposium on centralized volume-based procurement of pharmaceuticals.

BreakingsDec 30, 2024 13:18

Express News | Relevant departments, enterprises, and experts introduce information related to centralized procurement: the quality of Pharmaceutical products is strictly monitored, with comprehensive inspections of enterprises and random sampling of varieties.

BreakingsDec 30, 2024 12:12

Zhejiang Jingxin Pharmaceutical (002020.SZ): There are currently no plans to enter the Ophthalmology field.

Gelonghui December 26丨 Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company has no current plans to enter the Ophthalmology field.

Gelonghui FinanceDec 26, 2024 16:56

Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's diadizine is a globally innovative exclusive variety, with multiple patents still under protection.

Glory Financial, December 18 – Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company's dadarizine is a globally pioneering exclusive variety, and currently multiple patents are within the protection period.

Gelonghui FinanceDec 18, 2024 16:11

Express News | Aspirin oral immediate-release dosage form 14 enters 7, Zhejiang Jingxin Pharmaceutical intends to be the first bidder.

BreakingsDec 12, 2024 17:45

Zhejiang Jingxin Pharmaceutical (002020.SZ): The Phase II clinical trial of Kangfu Xinchangrong Capsules is currently in its final stages.

On December 3, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the Phase II clinical trial of the Rehabilitation New Enteric Capsule is nearing its conclusion, and the company will promptly advance the Phase III clinical trial of this product according to plan after completing Phase II.

Gelonghui FinanceDec 3, 2024 08:55

Zhejiang Jingxin Pharmaceutical's Insomnia Drug Added to National Medical Insurance Catalog

MT NewswiresNov 29, 2024 14:52

Express News | Over 20 listed companies announced after hours that pharmaceuticals have been included in the new national medical insurance catalog, with multiple innovative drugs among them.

BreakingsNov 28, 2024 22:23

Express News | Zhejiang Jingxin Pharmaceutical: Cidofovir capsules included in the national medical insurance catalog.

BreakingsNov 28, 2024 18:12